Stay updated on Neoadjuvant Pyrotinib in HER-2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Neoadjuvant Pyrotinib in HER-2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Neoadjuvant Pyrotinib in HER-2+ Breast Cancer Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    Revision: v3.5.0 was added and Revision: v3.4.3 was removed in the Record History to reflect the latest site release.
    Difference
    0.1%
    Check dated 2026-03-19T19:08:25.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    Added revision v3.4.3 to the record history, replacing v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-12T10:39:29.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2; removed the funding-lapse notice and Revision: v3.4.1.
    Difference
    0.9%
    Check dated 2026-02-11T16:27:57.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    Added a site-wide notice about a lapse in government funding affecting updates. Updated the page revision from v3.4.0 to v3.4.1.
    Difference
    0.9%
    Check dated 2026-02-04T10:41:39.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The history page now features a Show glossary option and green/red color-coded highlights to indicate additions and deletions. It also displays the Revision: v3.4.0 release note while substantive study data remain unchanged; to avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    1%
    Check dated 2026-01-28T06:36:40.000Z thumbnail image
  8. Check
    82 days ago
    Change Detected
    Summary
    Active, not recruiting as of 2026-01-07 is now shown, with new sections for Contacts/Locations, Eligibility, Outcome Measures, Arms and Interventions, Study Design, Study Description, Study Status, and Study Identification. The previous version listed Not yet recruiting and the last known status was Liu Yunjiang, Hebei Medical University Fourth Hospital.
    Difference
    2%
    Check dated 2026-01-14T02:23:05.000Z thumbnail image

Stay in the know with updates to Neoadjuvant Pyrotinib in HER-2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Neoadjuvant Pyrotinib in HER-2+ Breast Cancer Clinical Trial page.